What are ADC's

Our services

ADC Review
is made possible by:

NCT01771107 (Clinical Trial / Brentuximab Vedotin / SGN-035)

Study Title
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma (NCT01771107)

Trial Description
This pilot phase I/II trial studies the side effects and the best dose of brentuximab vedotin (also known as SGN-035) and combination chemotherapy work in treating patients with stage II-IV human immunodeficiency virus (HIV)-associated Hodgkin lymphoma.

Monoclonal antibody-drug conjugates or ADCs such as brentuximab vedotin can block cancer growth by finding cancer cells and causing them to die. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Giving brentuximab vedotin together with combination chemotherapy may kill more cancer cells.

This trial is sponsored by the National Cancer Institute (NCI). [1]

Study Data

  • Condition: Hodgkin Lymphoma
  • Interventions:
    • Other: Laboratory Biomarker Analysis
    • Other: Pharmacological Study
  • Phase: I & II
  • Estimated Enrollment: 51
  • Start: March 2013
  • Estimated Completion: June 2018 (Final data collection date for primary outcome measure)
  • Last verified: May 2015
  • Last updated: August 6, 2015

Study Schematic 

NCT01771107 (Clinical Trial / Brentuximab Vedotin)

Last Editorial review: July 21, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar